ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for Access

January 6, 2021

The Association for Clinical Oncology responded to two requests for information from the Department of Health and Human Services. One Request for Information sought stakeholder feedback and recommendations on which of the temporary regulatory flexibilities instituted during the COVID-19 Public Health Emergency (PHE) should be extended beyond the PHE. The other asked for information on leveraging novel technologies to manage chronic diseases in aging populations living in underserved areas.

January 6, 2021

On December 23, 2020, ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the Reducing Provider and Patient Burden and Promoting Patients' Electronic Access to Health Information proposed rule. This rule builds on the CMS Interoperability and Patient Access final rule and would require Medicaid and Children’s Health Insurance Program (CHIP) managed care plans, state Medicaid and CHIP fee-for-service programs, and Qualified Health Plan (QHP) issuers on federally facilitated insurance exchanges to improve the electronic exchange of health care data, and streamline processes related to prior authorization. 

January 6, 2021

Feasibility assessments (FA) for clinical trials are conducted to establish that prospective trial sites can safely and effectively meet study goals and protocol requirements, however, a new research statement by the American Society of Clinical Oncology (ASCO) asserts that current standards are “costly, inconsistent, inefficient, labor intensive, and of uncertain effectiveness.” These deficiencies ultimately result in fewer patients with timely access to clinical trials and delays in advancing novel safe and effective treatments.